navtemadlin
kartos therapeutics
['navtemadlin']
excited to see unreached overall survival in refractory setting of myelofibrosis with median followup of almost 40 months with navtemadlin ! excellently presented by at #eha23 . looking forward to the next development :) 
Leukemia doc interested in #leukemia, #MPN, #hematology. Tweets= my opinion.